CVS Health Corporation ($CVS) Stock Forecast: Up 5.6% Today

What is CVS Health Corporation?

CVS Health (CVS) is a prominent healthcare company that operates pharmacies, health clinics, and insurance services. The stock experienced a strong bullish movement today in the market.

Why is CVS Health Corporation going up?

CVS stock is up 5.6% on Dec 9, 2025 14:40

• CVS introduced a new consumer engagement platform, "Engagement as a Service," aimed at improving consumer interaction and partnerships. This strategic decision likely increased investor confidence and contributed to the bullish market movement.
• The company's optimistic profit forecast for 2026, driven by successful turnaround efforts and improved margins in key business units, may have impressed investors and generated a sense of positivity.
• While falling short of revenue projections for 2026, CVS's higher adjusted earnings outlook and commitment to strategic endeavors demonstrated resilience in a challenging retail and healthcare landscape, potentially reassuring shareholders.
• The mistrial in the opioid case involving CVS, Walmart, and Walgreens initially resulted in uncertainty. However, the absence of a unanimous verdict may have alleviated investors' concerns, leading to a favorable market response.

CVS Price Chart

CVS Technical Analysis

CVS News

CVS Health (CVS) Unveils New Consumer Engagement Platform

CVS Health (CVS) has launched "Engagement as a Service," a new technology platform aimed at enhancing consumer engagement by integrating services across its entities and with industry partners. Despite this strategic move, the company's financial performance shows mixed results, with concerns in profitability and debt management. Investors are advised to carefully consider these financial aspects alongside the new initiative.

https://www.gurufocus.com/news/3238861/cvs-health-cvs-unveils-new-consumer-engagement-platform

CVS forecasts 2026 profit above estimates as turnaround plan takes effect

CVS Health anticipates 2026 adjusted profit to be between $7.00 and $7.20 per share, surpassing analyst estimates due to a successful turnaround plan that included cost-cutting and market exits. The company, which also raised its 2025 profit outlook, attributes the growth to improved margins at its Aetna insurance business and CVS Caremark PBM unit. Despite a lower revenue forecast for 2026, the company's shares rose, reflecting renewed investor confidence.

https://www.cnbc.com/2025/12/09/cvs-forecasts-2026-profit-above-estimates-as-turnaround-plan-takes-effect.html

CVS Health Corp Updates Financial Guidance and Strategic Initiatives

CVS Health Corp updated its financial guidance and strategic priorities at its 2025 Investor Day on December 9, 2025. The company raised its 2025 revenue guidance to at least $400 billion, introduced 2026 revenue guidance of at least $400 billion, and committed to mid-teens Adjusted EPS CAGR through 2028. Additionally, CVS Health launched a new consumer engagement platform to simplify care and aims to transform consumer experiences and partnerships.

https://www.tradingview.com/news/tradingview:82473560dd3de:0-cvs-health-corp-updates-financial-guidance-and-strategic-initiatives/

CVS Forecasts 2026 Revenue Short of Wall Street Estimates

CVS Health Corp. has provided 2026 revenue guidance of at least $400 billion, falling short of Wall Street's average estimate of $418.3 billion. The company is facing a challenging retail environment and increased government scrutiny within the healthcare sector. However, its adjusted earnings forecast of up to $7.20 per share for 2026 surpassed analyst expectations.

https://www.bloomberg.com/news/articles/2025-12-09/cvs-forecasts-2026-revenue-short-of-wall-street-estimates

Florida hospitals' opioid case against Walmart, CVS, Walgreens results in mistrial

A Florida judge declared a mistrial in a lawsuit brought by sixteen Florida hospitals against Walmart, CVS, and Walgreens, which accused the pharmacy chains of contributing to the opioid crisis in the state. The jurors deliberated for 14 days but could not reach a unanimous verdict in the case alleging the companies flooded the state with opioids and violated anti-racketeering laws. The hospitals claimed that the surge in opioid use led to injuries they had to treat, often without reimbursement, racking up significant unpaid bills.

https://www.reuters.com/legal/litigation/florida-hospitals-opioid-case-against-walmart-cvs-walgreens-results-mistrial-2025-12-08/

Trending Today

Filecoin ($FIL) Crypto Forecast: Up 5.0% Today

PancakeSwap ($CAKE) Crypto Forecast: Down 5.1% Today

Silver ($XAG) Commodity Forecast: Up 5.0% Today

Beyond Meat Inc. ($BYND) Stock Forecast: Up 5.7% Today

Comcast Corporation Class A Common Stock ($CMCSA) Stock Forecast: Up 5.0% Today

National Oilwell Varco Inc. ($NOV) Stock Forecast: Down 5.1% Today

Phillips 66 ($PSX) Stock Forecast: Down 5.1% Today

Pfizer Inc. ($PFE) Stock Forecast: Down 5.1% Today

Humana Inc. ($HUM) Stock Forecast: Down 5.1% Today

Cytokinetics, Incorporated ($CYTK) Stock Forecast: Down 5.0% Today

CVS Health Corporation Price History

17.03.2025 - CVS Stock was down 7.2%

• CVS stock saw a decline of -0.55% and -1.87% in recent trading sessions.
• A comparison between CVS Health and UnitedHealth may have influenced investors' decisions, leading to some selling pressure on CVS stock.
• Uncertainty around healthcare policies and regulations may have also affected the bearish trend in CVS stock.
• Monitoring upcoming developments in the healthcare sector is crucial for investors to gauge the performance of CVS Health stock.

09.11.2025 - CVS Stock was up 5.6%

• CVS introduced a new consumer engagement platform, "Engagement as a Service," aimed at improving consumer interaction and partnerships. This strategic decision likely increased investor confidence and contributed to the bullish market movement.
• The company's optimistic profit forecast for 2026, driven by successful turnaround efforts and improved margins in key business units, may have impressed investors and generated a sense of positivity.
• While falling short of revenue projections for 2026, CVS's higher adjusted earnings outlook and commitment to strategic endeavors demonstrated resilience in a challenging retail and healthcare landscape, potentially reassuring shareholders.
• The mistrial in the opioid case involving CVS, Walmart, and Walgreens initially resulted in uncertainty. However, the absence of a unanimous verdict may have alleviated investors' concerns, leading to a favorable market response.

24.06.2025 - CVS Stock was down 5.1%

• Despite the anticipation of surpassing earnings expectations and encouraging indications of a possible revival, CVS stock faced a significant downtrend.
• The decrease in Q2 earnings predictions and worries regarding the company's performance might have overshadowed the positive developments, contributing to the market's bearish movement.
• Investors could have responded unfavorably to the uncertainties surrounding CVS's future performance, notwithstanding the company's efforts to enhance its Health Care Benefits division and potential signs of a turnaround.
• Despite the stock being technically oversold and receiving favorable evaluations from analysts, these factors may not have been sufficient to counterbalance the existing concerns, resulting in CVS's bearish trajectory today.

30.09.2025 - CVS Stock was down 7.3%

• Despite surpassing third-quarter earnings projections and increasing annual guidance, CVS stock faced a decline in value.
• It is possible that the market responded negatively as some investors were anticipating even more robust results despite the positive earnings and revenue outcomes.
• The decline in CVS stock could also be linked to some investors seizing gains after expecting a more significant market response.
• The CEO's initiatives to boost profits and enhance stock performance may not have fully convinced investors about the company's potential for long-term growth, which contributed to the stock's decline.

31.06.2025 - CVS Stock was up 6.4%

• CVS Health (CVS) exceeded both earnings and revenue estimates for the second quarter, showcasing strong financial performance and potentially indicating positive growth prospects.
• Analysts revised their expectations for CVS Health ahead of its earnings release, with a slight decrease in projected quarterly earnings per share compared to the previous year.
• Despite concerns about rising medical costs, CVS' Health Care Delivery unit demonstrated robust growth, driven by key partnerships with Signify and Oak Street, which likely contributed to investor optimism.
• The stock's recent slide amidst a rising market might be attributed to short-term fluctuations or profit-taking, rather than reflecting any fundamental issues with the company's performance.

01.04.2025 - CVS Stock was up 6.9%

• CVS Health outperformed expectations in the first quarter, prompting an increase in its full-year EPS guidance, which in turn boosted its stock value.
• A partnership with Novo Nordisk to improve access to Wegovy, a weight loss treatment, for CVS drug plan members played a role in boosting investor confidence.
• The company's strong financial results, highlighted by a sharp increase in adjusted EPS and operating income, bolstered the upward momentum of the stock.
• The market's positive reaction demonstrates faith in CVS's strategies and financial performance, leading to upward movement in the stock price even amidst market volatility.

01.04.2025 - CVS Stock was up 9.7%

• CVS Health (CVS) saw a notable upward movement in trading today.
• The company's Q1 earnings and revenues surpassed market expectations by a substantial margin, which likely instilled confidence among investors.
• The decision to prioritize Novo Nordisk's weight loss treatment Wegovy on its formulary may have also contributed to the positive market sentiment, hinting at potential growth avenues and improved healthcare offerings.
• Analysts' positive projections for CVS Health's earnings growth, along with the anticipation of a robust earnings performance, may have additionally bolstered the bullish momentum, attracting increased investor interest in the stock.

02.04.2025 - CVS Stock was down 4.4%

• CVS Health reported better-than-expected first-quarter results and raised its FY25 EPS guidance, leading to a sharp rise in its stock price.
• The partnership with Wegovy maker Novo Nordisk and the significant improvement in adjusted EPS and operating income contributed to the positive market sentiment towards CVS.
• The earnings and revenue beats in Q1 2025, along with the raised EPS view, further fueled investor confidence in CVS Health, driving the stock price higher.
• Despite the positive news and strong financial performance, the market might have reacted bearishly due to profit-taking or broader market factors impacting CVS's stock price negatively.

02.08.2025 - CVS Stock was up 1.3%

• The positive momentum in its Health Care Benefit segment, driven by government plans despite facing utilization pressures, contributed to the bullish movement in CVS stock today.
• Strong investor confidence in CVS's future prospects and fundamental strength is reflected in the stock hitting a 52-week high.
• Investors may currently view CVS as a better value and stronger investment option compared to other healthcare stocks like HealthEquity and Elevance.
• CVS's focus on Aetna margin recovery, digital investments, and cost savings is resonating well with investors, contributing to the bullish market movement.

13.04.2025 - CVS Stock was down 5.2%

• The decline in CVS stock value could be linked to a recent executive order that aims to align U.S. drug prices with those of other countries, potentially impacting the company's financial performance.
• Although there were positive sentiments in options trading, the general market outlook has shifted negatively, resulting in the drop in CVS stock.
• Glenview Capital's remarks about CVS Health's progress in its long-term transformation might have been overshadowed by broader market anxieties, contributing to the stock's downturn.
• Investor perception of CVS Health compared to other industry peers may have also played a role in the stock price decrease.

13.04.2025 - CVS Stock was down 7.0%

• The bearish movement in CVS stock today could be attributed to investors potentially favoring Danaher (DHR) over CVS as a better value option in the Medical Services sector.
• Glenview Capital's statement on CVS Health may have failed to reassure investors about the company's long-term turnaround plans, leading to a lack of confidence in CVS stock.
• The overall sentiment in the market towards healthcare stocks might have also contributed to the bearish movement in CVS, as investors may be cautious about regulatory impacts and competitive pressures in the sector.

29.09.2025 - CVS Stock was up 0.3%

• CVS outperformed Q3 earnings and revenue projections by a considerable margin.
• CEO David Joyner's successful first year at CVS led to improved profits and stock performance, bolstering investor faith.
• Recent advancements within CVS's Pharmacy & Consumer Wellness division, such as technological enhancements and strategic acquisitions, supported the stock's upward trajectory.
• Despite a slight dip in the stock price during the last trading session, the optimistic news and outlook surrounding CVS have attracted investor attention and confidence in the company's future growth prospects.